Xenon Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Xenon Pharmaceuticals Inc (XENE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.9% of the shares are freely tradable; institutional investors hold 107.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 9.96 | 9,647,998 | -10.8 | 06/30/2026 |
| BlackRock Inc | 7.77 | 7,522,482 | +33.4 | 06/30/2026 |
| venBio Select Advisor LLC | 5.97 | 5,777,777 | +0.0 | 06/30/2026 |
| Polar Capital Holdings PLC | 4.72 | 4,570,556 | +3.8 | 06/30/2026 |
| Driehaus Capital Management LLC | 4.56 | 4,418,557 | -1.6 | 06/30/2026 |
| Jupiter Topco LLC | 4.32 | 4,186,519 | +0.0 | 06/30/2026 |
| HHG PLC | 4.31 | 4,175,982 | +2.3 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 3.35 | 3,248,219 | +144.3 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 2.91 | 2,814,992 | -9.9 | 09/30/2026 |
| Polar Capital Biotech S Inc | 2.81 | 2,720,970 | +0.0 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Mortimer Ian | PRESIDENT & CEO | 49,923 | 1,867,120 $ | Sep 30, 2026 | direct |
| Svoronos Dawn | Director | 31,373 | 1,173,350 $ | Sep 1, 2026 | direct |
| Kelly Thomas Patrick | Chief Financial Officer | 22,500 | 841,500 $ | Oct 15, 2026 | direct |
| Gannon Steven | Director | 1,870 | 69,938 $ | Aug 11, 2026 | direct |
| Kenney Christopher John | Chief Medical Officer | 2 | 75 $ | Aug 28, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Kelly Thomas Patrick | Chief Financial Officer | Other | 7,500 | – | – |
| Sep 30, 2026 | Kelly Thomas Patrick | Chief Financial Officer | Buy | 15,000 | 37.32 | 559,740 |
| Sep 30, 2026 | Mortimer Ian | PRESIDENT & CEO | Buy | 30,000 | 37.38 | 1,121,400 |
| Sep 1, 2026 | Svoronos Dawn | Director | Other | 5,144 | 8.15 | 41,924 |
| Aug 28, 2026 | Kenney Christopher John | Chief Medical Officer | Sell | 700 | 60.98 | 42,684 |
| Aug 28, 2026 | Kenney Christopher John | Chief Medical Officer | Sell | 6,368 | 60.17 | 383,145 |
| Aug 11, 2026 | Gannon Steven | Director | Sell | 10,000 | 64.06 | 640,550 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.